DULAGLUTIDE
Abnormal Glucose Tolerance
University of Pennsylvaniaprotein_peptidePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Abnormal Glucose Tolerance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DULAGLUTIDE The University of Texas Health Science Center, Houston | Phase 4 | BB |
NEPENTHE Washington University School of Medicine | Phase 4 | BB |
Bxcl501 Pontificia Universidad Catolica de Chile | Phase 4 | BB |
CYANOCOBALAMINUM The University of Texas Health Science Center, Houston | Phase 4 | BB |
FENTANYL Pontificia Universidad Catolica de Chile | Phase 4 | BB |
View all 16 →
Same molecule, other indications
DULAGLUTIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →